These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33782144)

  • 1. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis.
    Allen Reeves A; Fuentes AV; Caballero J; Thomas JE; Mosley Ii JF; Harrington C
    Sex Transm Infect; 2021 Jun; 97(4):261-267. PubMed ID: 33782144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
    Turkova A; White E; Mujuru HA; Kekitiinwa AR; Kityo CM; Violari A; Lugemwa A; Cressey TR; Musoke P; Variava E; Cotton MF; Archary M; Puthanakit T; Behuhuma O; Kobbe R; Welch SB; Bwakura-Dangarembizi M; Amuge P; Kaudha E; Barlow-Mosha L; Makumbi S; Ramsagar N; Ngampiyaskul C; Musoro G; Atwine L; Liberty A; Musiime V; Bbuye D; Ahimbisibwe GM; Chalermpantmetagul S; Ali S; Sarfati T; Wynne B; Shakeshaft C; Colbers A; Klein N; Bernays S; Saïdi Y; Coelho A; Grossele T; Compagnucci A; Giaquinto C; Rojo P; Ford D; Gibb DM;
    N Engl J Med; 2021 Dec; 385(27):2531-2543. PubMed ID: 34965338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
    Cento V; Perno CF
    J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
    Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
    N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
    Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
    Moyle G; Assoumou L; de Castro N; Post FA; Curran A; Rusconi S; De Wit S; Stephan C; Raffi F; Johnson M; Masia M; Vera J; Jones B; Grove R; Fletcher C; Duffy A; Morris K; Pozniak A;
    Lancet HIV; 2024 Mar; 11(3):e156-e166. PubMed ID: 38417976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV.
    Ramos-Ruperto L; Arcos-Rueda MDM; de Miguel-Buckley R; Busca-Arenzana C; Mican R; Montejano R; Delgado-Hierro A; Montes ML; Valencia ME; Serrano L; Arribas JR; González J; Bernardino JI; Martín-Carbonero L
    HIV Med; 2024 Jun; 25(6):684-691. PubMed ID: 38379338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV.
    van der Wekken-Pas L; Nassiwa S; Malaba T; Lamorde M; Myer L; Waitt C; Reynolds H; Khoo S; He N; van Leeuwen L; Burger D; Wang D; Colbers A
    AIDS; 2024 Jun; 38(7):975-981. PubMed ID: 38277390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study.
    Nightingale S; Dreyer AJ; Thomas KGF; van Zyl G; Decloedt E; Naude PJW; Orrell C; Sinxadi P; Winston A; Khoo S; Joska JA
    Lancet HIV; 2024 Oct; 11(10):e680-e689. PubMed ID: 39284338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in functional connectivity in people with HIV switching antiretroviral therapy.
    Toniolo S; Cercignani M; Mora-Peris B; Underwood J; Alagaratnam J; Bozzali M; Boffito M; Nelson M; Winston A; Vera JH
    J Neurovirol; 2020 Oct; 26(5):754-763. PubMed ID: 32500477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
    Griesel R; Maartens G; Chirehwa M; Sokhela S; Akpomiemie G; Moorhouse M; Venter F; Sinxadi P
    Clin Infect Dis; 2021 Dec; 73(11):e3902-e3909. PubMed ID: 32960272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study.
    Mellgren Å; Eriksson LE; Reinius M; Marrone G; Svedhem V
    PLoS One; 2020; 15(12):e0242710. PubMed ID: 33362248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
    Dorward J; Sookrajh Y; Lessells R; Bulo E; Bodley N; Singh L; Moodley P; Samsunder N; Drain PK; Hayward G; Butler CC; Garrett N
    J Acquir Immune Defic Syndr; 2024 Apr; 95(5):e8-e11. PubMed ID: 38489494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir.
    Zimba S; Mbewe N; Chishimba L; Chomba M; Saylor D
    Trop Doct; 2021 Apr; 51(2):216-218. PubMed ID: 32903146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fetal biometry following in-utero exposure to dolutegravir-based or efavirenz-based antiretroviral therapy.
    Banda FM; Powis KM; Sun S; Makhema J; Masasa G; Yee LM; Jao J
    AIDS; 2020 Dec; 34(15):2336-2337. PubMed ID: 32910067
    [No Abstract]   [Full Text] [Related]  

  • 18. Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances.
    Lapadula G; Bernasconi DP; Bai F; Focà E; Di Biagio A; Bonora S; Castelli F; Squillace N; Bandera A; Monforte AD; Migliorino GM; Gori A;
    AIDS; 2020 Jan; 34(1):53-61. PubMed ID: 31567160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
    Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.